da CostaRMRodriguesDPereiraCASilvaJFAlvesJVLobatoNSet alNrf2 as a potential mediator of cardiovascular risk in metabolic diseases
First Signals of Change Many patients report reduced appetite and feeling full sooner than usual, which is the medication starting to work
Who may qualify for tirzepatide treatment
Selective SGLT2 inhibitors block glucose reabsorption in the proximal renal tubule, increasing glucose elimination and reducing hyperglycemia
Peer review Peer review information Nature Reviews Nephrology thanks Lin Sun, Mattias Carlstrom and the other, anonymous, reviewer(s) for their contribution to the peer review of this work
A large N-terminal extracellular domain (ECD) captures the C-terminal portion of peptide ligands through a "catch and release" mechanism, while the ligand's N-terminal region inserts into the transmembrane domain (TMD) to activate the receptor